Cargando…
The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
Background: The antiproliferative activity of a high dose of somatostatin analogs (HD-SSA) in treating gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) remains under debate. Methods: A systematic review and proportion meta-analysis were made. The primary endpoint was the efficacy measure...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605244/ https://www.ncbi.nlm.nih.gov/pubmed/36294448 http://dx.doi.org/10.3390/jcm11206127 |
_version_ | 1784818018012889088 |
---|---|
author | Panzuto, Francesco Ricci, Claudio Rinzivillo, Maria Magi, Ludovica Marasco, Matteo Lamberti, Giuseppe Casadei, Riccardo Campana, Davide |
author_facet | Panzuto, Francesco Ricci, Claudio Rinzivillo, Maria Magi, Ludovica Marasco, Matteo Lamberti, Giuseppe Casadei, Riccardo Campana, Davide |
author_sort | Panzuto, Francesco |
collection | PubMed |
description | Background: The antiproliferative activity of a high dose of somatostatin analogs (HD-SSA) in treating gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) remains under debate. Methods: A systematic review and proportion meta-analysis were made. The primary endpoint was the efficacy measured as incidence density ratio (IDR) at one year. The secondary endpoints were the disease control rate (DCR) and severe adverse events (SAEs). The heterogeneity (I2), when high (>50%), was interpreted by performing a univariate metaregression analysis, analyzing as covariates: type and design of the study, location (Europe or USA), sample size, grading according to 2017 WHO, the metastatic disease rate, previous therapy including surgery, and quality of the study. Results: A total of 11 studies with 783 patients were included. The IDR was 62 new progressions of 100 patients treated with HD-SSA every one year. The heterogeneity was high. The study’s year, type and design, primary tumor, grading, previous treatments, and quality of the studies did not influence the IDR. The IDR was significantly higher in USA centers and studies with more than 50 patients. The IDR was lower when a high rate of metastatic patients was present in the studies. The DCR was 45%. The heterogeneity was high. The DCR was lower in USA studies and in prospective trials. Conclusion: Given the limited efficacy of HD-SSA in preventing the disease progression in unresectable GEP-NENs after failure of standard dose SSA, the use of this therapeutic approach is advisable in selected cases when other antiproliferative treatments are not feasible. |
format | Online Article Text |
id | pubmed-9605244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96052442022-10-27 The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis Panzuto, Francesco Ricci, Claudio Rinzivillo, Maria Magi, Ludovica Marasco, Matteo Lamberti, Giuseppe Casadei, Riccardo Campana, Davide J Clin Med Article Background: The antiproliferative activity of a high dose of somatostatin analogs (HD-SSA) in treating gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) remains under debate. Methods: A systematic review and proportion meta-analysis were made. The primary endpoint was the efficacy measured as incidence density ratio (IDR) at one year. The secondary endpoints were the disease control rate (DCR) and severe adverse events (SAEs). The heterogeneity (I2), when high (>50%), was interpreted by performing a univariate metaregression analysis, analyzing as covariates: type and design of the study, location (Europe or USA), sample size, grading according to 2017 WHO, the metastatic disease rate, previous therapy including surgery, and quality of the study. Results: A total of 11 studies with 783 patients were included. The IDR was 62 new progressions of 100 patients treated with HD-SSA every one year. The heterogeneity was high. The study’s year, type and design, primary tumor, grading, previous treatments, and quality of the studies did not influence the IDR. The IDR was significantly higher in USA centers and studies with more than 50 patients. The IDR was lower when a high rate of metastatic patients was present in the studies. The DCR was 45%. The heterogeneity was high. The DCR was lower in USA studies and in prospective trials. Conclusion: Given the limited efficacy of HD-SSA in preventing the disease progression in unresectable GEP-NENs after failure of standard dose SSA, the use of this therapeutic approach is advisable in selected cases when other antiproliferative treatments are not feasible. MDPI 2022-10-18 /pmc/articles/PMC9605244/ /pubmed/36294448 http://dx.doi.org/10.3390/jcm11206127 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Panzuto, Francesco Ricci, Claudio Rinzivillo, Maria Magi, Ludovica Marasco, Matteo Lamberti, Giuseppe Casadei, Riccardo Campana, Davide The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis |
title | The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis |
title_full | The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis |
title_fullStr | The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis |
title_full_unstemmed | The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis |
title_short | The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis |
title_sort | antiproliferative activity of high-dose somatostatin analogs in gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605244/ https://www.ncbi.nlm.nih.gov/pubmed/36294448 http://dx.doi.org/10.3390/jcm11206127 |
work_keys_str_mv | AT panzutofrancesco theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT ricciclaudio theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT rinzivillomaria theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT magiludovica theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT marascomatteo theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT lambertigiuseppe theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT casadeiriccardo theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT campanadavide theantiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT panzutofrancesco antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT ricciclaudio antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT rinzivillomaria antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT magiludovica antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT marascomatteo antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT lambertigiuseppe antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT casadeiriccardo antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis AT campanadavide antiproliferativeactivityofhighdosesomatostatinanalogsingastroenteropancreaticneuroendocrinetumorsasystematicreviewandmetaanalysis |